---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-016464"
form_type: "8-K"
ticker: "ASTH"
cik: "0001083446"
company_name: "Astrana Health, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:10:39.377890+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ApolloMed Q1 revenue $337M (+28% YoY), EPS $0.31 flat; appoints Chan Basho CFO

## Summary
- Q1 revenue $337.2M (+28% YoY), net income attributable $14.6M (+3%), diluted EPS $0.31 (flat YoY).
- Adjusted EBITDA $29.8M vs $34.4M, decrease driven by higher investments and non-cash gains.
- Chan Basho appointed permanent CFO (was interim); will remain Chief Strategy Officer.
- Acquired For Your Benefit (FYB) and received CA DMHC approval for Knox-Keene health plan, enabling global risk assumption.
- Reaffirms FY23 guidance: revenue $1.3B-$1.5B, net income $49.5M-$71.5M, adj EBITDA $120M-$160M, EPS $0.95-$1.20.

## SEC filing metadata
- accession: 0001628280-23-016464
- form_type: 8-K
- ticker: ASTH
- cik: 0001083446
- company_name: Astrana Health, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1083446/000162828023016464/0001628280-23-016464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1083446/000162828023016464/ameh-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-016464
- JSON: https://secwatch.observer/filing/0001628280-23-016464.json
- Plain text: https://secwatch.observer/filing/0001628280-23-016464.txt

## Key facts
- Earnings Releases
  Astrana Health, Inc. reported first quarter ended March 31, 2023 results: revenue $337.2 million, net income $14.6 million, EPS $0.31. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $337.2 million
  - Net income: $14.6 million
  - EPS: $0.31
  - Guidance: reaffirmed
  - Result: reported results
  source text: Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the first quarter ended March 31, 2023. Financial Highlights for First Quarter Ended March 31, 2023: • Total revenue of $337.2 million, up 28% from $263.3 million for the prior-year quarter • Net income attributable to ApolloMed of $14.6 million, up 3% from $14.3 million for the prior-year quarter • Earnings per share - diluted (“EPS - diluted”) of $0.31, compared to $0.31 per share for the prior-year quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1083446/000162828023016464/0001628280-23-016464-index.htm
- Executive change
  Chan Basho was appointed as Chief Financial Officer at Astrana Health, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1083446/000162828023016464/0001628280-23-016464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.